Development of a screen to identify selective small molecules active against patient-derived metastatic and chemoresistant breast cancer cells

Breast Cancer Research

Volumn 15, Issue 4, 2013, Pages

  Gligorich, Keith M ^a   Vaden, Rachel M ^b   Shelton, Dawne N ^a   Wang, Guoying ^a   Matsen, Cindy B ^a   Looper, Ryan E ^b   Sigman, Matthew S ^b   Welm, Bryan E ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; HEXAMETHONIUM BROMIDE; TELOMERASE; MOLECULAR LIBRARY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; BREAST REDUCTION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENICITY; CELL CYCLE; CELL DEATH; CELL HETEROGENEITY; CELL IMMORTALIZATION; CELL PROLIFERATION; CHEMORESISTANT BREAST CANCER; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PLEURA EFFUSION; ANIMAL; BREAST NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOPHENOTYPING; METABOLISM; METASTASIS; MOLECULAR LIBRARY; PATHOLOGY; PHENOTYPE; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CASPASES; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMMUNOPHENOTYPING; NEOPLASM METASTASIS; PHENOTYPE; POLY(ADP-RIBOSE) POLYMERASES; SMALL MOLECULE LIBRARIES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880334296     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3452     Document Type: Article

References (44)

1. Moulder S, Hortobagyi GN. Advances in the treatment of breast cancer. Clin Pharmacol Ther 2008, 83:26-36. 10.1038/sj.clpt.6100449, 18091763.
2. Swain SM. Chemotherapy: updates and new perspectives. Oncologist 2011, 16:30-39. 10.1634/theoncologist.2011-S1-30, 21278439.
3. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA: Cancer J Clin 2011, 61:408-418.
4. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007, 608:1-22. 10.1007/978-0-387-74039-3_1, 17993229.
5. Azim HA, de Azambuja E, Colozza M, Bines J, Piccart MJ. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol 2011, 22:1939-1947. 10.1093/annonc/mdq683, 21289366.
6. Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult?. Nat Rev Drug Discov 2007, 6:115-120. 10.1038/nrd2155, 17159925.
7. Hait WN. Anticancer drug development: the grand challenges. Nat Rev Drug Discov 2010, 9:253-254. 10.1038/nrd3144, 20369394.
8. Burdall S, Hanby A, Lansdown M, Speirs V. Breast cancer cell lines: friend or foe?. Breast Cancer Res 2003, 5:89-95. 10.1186/bcr577, 154155, 12631387.
9. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
10. Holliday D, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res 2011, 13:215. 10.1186/bcr2889, 3236329, 21884641.
11. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24:227-235. 10.1038/73432, 10700174.
12. Hiorns LR, Bradshaw TD, Skelton LA, Yu Q, Kelland LR, Leyland-Jones B. Variation in RNA expression and genomic DNA content acquired during cell culture. Br J Cancer 2004, 90:476-482. 10.1038/sj.bjc.6601405, 2409579, 14735196.
13. Tsuji K, Kawauchi S, Saito S, Furuya T, Ikemoto K, Nakao M, Yamamoto S, Oka M, Hirano T, Sasaki K. Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues. BMC Cancer 2010, 10:15. 10.1186/1471-2407-10-15, 2836299, 20070913.
14. Keller P, Lin A, Arendt L, Klebba I, Jones A, Rudnick J, DiMeo T, Gilmore H, Jefferson D, Graham R, Naber S, Schnitt S, Kuperwasser C. Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines. Breast Cancer Res 2010, 12:R87. 10.1186/bcr2755, 3096980, 20964822.
15. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 2007, 7:791-799. 10.1038/nrc2212, 17851544.
16. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
17. Speirs V, Green AR, Walton DS, Kerin MJ, Fox JN, Carelton PJ, Desai SB, Atkin SL. Short-term primary culture of epithelial cells derived from human breast tumours. Br J Cancer 1998, 78:1421-1429. 10.1038/bjc.1998.702, 2063218, 9836473.
18. Dairkee S, Ji Y, Ben Y, Moore D, Meng Z, Jeffrey S. A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics 2004, 5:47. 10.1186/1471-2164-5-47, 509241, 15260889.
19. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu M-F, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-679. 10.1093/jnci/djn123, 18445819.
20. DeRose YS, Gligorich KM, Wang G, Georgelas A, Bowman P, Courdy SJ, Welm BE, Welm AL. Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications. Curr Protoc Pharmacol 2013, Chapter 14. Unit14.23.
21. Garbe JC, Bhattacharya S, Merchant B, Bassett E, Swisshelm K, Feiler HS, Wyrobek AJ, Stampfer MR. Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells. Cancer Res 2009, 69:7557-7568. 10.1158/0008-5472.CAN-09-0270, 2782785, 19773443.
22. Gligorich KM, Cummings SA, Sigman MS. Palladium-catalyzed reductive coupling of styrenes and organostannanes under aerobic conditions. J Am Chem Soc 2007, 129:14193-14195. 10.1021/ja076746f, 17963397.
23. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, Weinberg RA. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001, 15:50-65. 10.1101/gad.828901, 312602, 11156605.
24. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999, 4:67-73. 10.1177/108705719900400206, 10838414.
25. Villadsen R, Fridriksdottir AJ, Rønnov-Jessen L, Gudjonsson T, Rank F, LaBarge MA, Bissell MJ, Petersen OW. Evidence for a stem cell hierarchy in the adult human breast. J Cell Biol 2007, 177:87-101. 10.1083/jcb.200611114, 2064114, 17420292.
26. Stanton PD, Cooke TG, Forster G, Smith D, Going JJ. Cell kinetics in vivo of human breast cancer. Br J Surg 1996, 83:98-102. 10.1002/bjs.1800830130, 8653378.
27. El Saghir NS, Tfayli A, Hatoum HA, Nachef Z, Dinh P, Awada A. Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Crit Rev Oncol-Hem 2011, 80:433-449.
28. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008, 1785:96-132.
29. Dent S, Messersmith H, Trudeau M. Gemcitabine in the management of metastatic breast cancer: a systematic review. Breast Cancer Res Treat 2008, 108:319-331. 10.1007/s10549-007-9610-z, 17530427.
30. Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W, Lomas C, Mendiola M, Hardisson D, Eccles S. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol 2012, 10:29. 10.1186/1741-7007-10-29, 3349530, 22439642.
31. Ewald AJ, Brenot A, Duong M, Chan BS, Werb Z. Collective epithelial migration and cell rearrangements drive mammary branching morphogenesis. Dev Cell 2008, 14:570-581. 10.1016/j.devcel.2008.03.003, 2773823, 18410732.
32. Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, Lupu R, Bissell MJ. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci USA 1998, 95:14821-14826. 10.1073/pnas.95.25.14821, 24533, 9843973.
33. Fulda S, Gorman AM, Hori O, Samali A. Cellular stress responses: cell survival and cell death. Int J Cell Biol 2010, 2010:214074. 2825543, 20182529.
34. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S, Lipton SA, Lu X, Madeo F, Malorni W, Mehlen P, Nunez G, Peter ME, Piacentini M, Rubinsztein DC, Shi Y, Simon HU, Vandenabeele P, White E, Yuan J, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012, 19:107-120. 10.1038/cdd.2011.96, 3252826, 21760595.
35. Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res 2005, 11:3155-3162. 10.1158/1078-0432.CCR-04-2223, 15867207.
36. Rosenfeldt MT, Ryan KM. The role of autophagy in tumour development and cancer therapy. Expert Rev Mol Med 2009, 11:e36. 2811398, 19951459.
37. Mizushima N. Methods for monitoring autophagy. Int J Biochem Cell Bio 2004, 36:2491-2502.
38. Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 2007, 13:7271-7279. 10.1158/1078-0432.CCR-07-1595, 18094407.
39. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659. 10.1016/j.cell.2009.06.034, 19682730.
40. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011, 17:1514-1520. 10.1038/nm.2454, 3553601, 22019887.
41. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R. Statistical practice in high-throughput screening data analysis. Nat Biotech 2006, 24:167-175.
42. Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ, Los M. Apoptosis and cancer: mutations within caspase genes. J Med Genet 2009, 46:497-510. 10.1136/jmg.2009.066944, 19505876.
43. Simstein R, Burow M, Parker A, Weldon C, Beckman B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med 2003, 228:995-1003.
44. Végran F, Boidot R, Oudin C, Riedinger JM, Bonnetain F, Lizard-Nacol S. Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clin Cancer Res 2006, 12:5794-5800. 10.1158/1078-0432.CCR-06-0725, 17020986.